Segall Bryant & Hamill LLC Has $22.96 Million Holdings in Allergan PLC. (AGN)
Segall Bryant & Hamill LLC lessened its stake in shares of Allergan PLC. (NYSE:AGN) by 11.7% during the third quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 112,046 shares of the company’s stock after selling 14,839 shares during the quarter. Segall Bryant & Hamill LLC’s holdings in Allergan were worth $22,964,000 at the end of the most recent reporting period.
Several other hedge funds have also bought and sold shares of the company. Hudock Capital Group LLC boosted its holdings in shares of Allergan by 0.4% during the second quarter. Hudock Capital Group LLC now owns 571 shares of the company’s stock worth $138,000 after purchasing an additional 2 shares during the last quarter. Burns J W & Co. Inc. NY boosted its holdings in shares of Allergan by 0.7% during the second quarter. Burns J W & Co. Inc. NY now owns 906 shares of the company’s stock worth $220,000 after purchasing an additional 6 shares during the last quarter. Pacific Center for Financial Services boosted its holdings in shares of Allergan by 1.3% during the second quarter. Pacific Center for Financial Services now owns 541 shares of the company’s stock worth $132,000 after purchasing an additional 7 shares during the last quarter. Gilder Gagnon Howe & Co. LLC boosted its holdings in shares of Allergan by 0.5% during the second quarter. Gilder Gagnon Howe & Co. LLC now owns 1,666 shares of the company’s stock worth $405,000 after purchasing an additional 9 shares during the last quarter. Finally, Trust Co boosted its holdings in shares of Allergan by 0.8% during the first quarter. Trust Co now owns 1,224 shares of the company’s stock worth $292,000 after purchasing an additional 10 shares during the last quarter. Institutional investors and hedge funds own 81.34% of the company’s stock.
AGN has been the topic of a number of research analyst reports. Argus reiterated a “buy” rating and issued a $280.00 target price on shares of Allergan in a report on Monday, August 14th. Deutsche Bank reiterated a “buy” rating and issued a $278.00 target price (up previously from $273.00) on shares of Allergan in a report on Wednesday, August 9th. Royal Bank Of Canada reiterated a “buy” rating and issued a $285.00 target price on shares of Allergan in a report on Wednesday, September 6th. Citigroup reiterated a “buy” rating and issued a $280.00 target price on shares of Allergan in a report on Wednesday, September 20th. Finally, Mizuho reiterated a “buy” rating and issued a $267.00 target price on shares of Allergan in a report on Monday, September 25th. One analyst has rated the stock with a sell rating, eight have assigned a hold rating and fourteen have assigned a buy rating to the company’s stock. Allergan currently has an average rating of “Buy” and a consensus price target of $241.56.
In other Allergan news, Director Christopher J. Coughlin bought 10,000 shares of the company’s stock in a transaction dated Tuesday, December 5th. The shares were acquired at an average cost of $163.30 per share, with a total value of $1,633,000.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider William Meury sold 11,807 shares of Allergan stock in a transaction dated Friday, December 1st. The stock was sold at an average price of $173.89, for a total value of $2,053,119.23. The disclosure for this sale can be found here. 0.36% of the stock is currently owned by insiders.
Shares of Allergan PLC. (AGN) opened at $168.00 on Thursday. Allergan PLC. has a 52-week low of $160.07 and a 52-week high of $256.80. The stock has a market capitalization of $54,636.75, a PE ratio of 10.65, a PEG ratio of 1.10 and a beta of 1.11. The company has a debt-to-equity ratio of 0.40, a quick ratio of 1.08 and a current ratio of 1.18.
Allergan (NYSE:AGN) last announced its earnings results on Wednesday, November 1st. The company reported $4.15 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $4.06 by $0.09. Allergan had a positive return on equity of 8.00% and a negative net margin of 47.27%. The business had revenue of $4.03 billion for the quarter, compared to analyst estimates of $4.04 billion. During the same period in the previous year, the company earned $3.32 earnings per share. The company’s revenue for the quarter was up 11.4% compared to the same quarter last year. research analysts predict that Allergan PLC. will post 16.28 EPS for the current year.
The firm also recently announced a quarterly dividend, which will be paid on Friday, December 15th. Stockholders of record on Friday, November 17th will be given a dividend of $0.70 per share. This represents a $2.80 dividend on an annualized basis and a dividend yield of 1.67%. The ex-dividend date of this dividend is Thursday, November 16th. Allergan’s payout ratio is -12.44%.
Allergan declared that its board has approved a share buyback program on Monday, September 25th that permits the company to repurchase $2.00 billion in shares. This repurchase authorization permits the company to repurchase up to 2.8% of its stock through open market purchases. Stock repurchase programs are typically a sign that the company’s board believes its shares are undervalued.
COPYRIGHT VIOLATION NOTICE: “Segall Bryant & Hamill LLC Has $22.96 Million Holdings in Allergan PLC. (AGN)” was first posted by Daily Political and is owned by of Daily Political. If you are accessing this news story on another website, it was illegally copied and republished in violation of US and international copyright legislation. The correct version of this news story can be viewed at https://www.dailypolitical.com/2017/12/07/segall-bryant-hamill-llc-has-22-96-million-holdings-in-allergan-plc-agn.html.
Allergan, Inc is a multi-specialty healthcare company. The Company focuses on developing and commercializing pharmaceuticals, biologics, medical devices and over-the-counter (OTC) products. It discovers, develops and commercializes a range of products for the ophthalmic, neurological, medical aesthetics, medical dermatology, breast aesthetics, urological and other specialty markets.
Receive News & Ratings for Allergan PLC. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allergan PLC. and related companies with MarketBeat.com's FREE daily email newsletter.